Whether acetyl-L-carnitine, which failed to verify its efficacy in its ‘secondary degenerative diseases caused by cerebrovascular disease’ indication during clinical reevaluations, will be able to maintain its marketing authorization status will be determined within September this year.

The Ministry of Food and Drug Safety issued a Dear Healthcare Professional Letter on the 5th recommending the use of alternative drugs and discontinuing the prescription and dispensing of drugs that contain acetyl-L-carnitine.

At the MFDS correspondents’ briefing held on the 9th, Kyung Seung Shin, Director of the Pharmaceutical Safety Evaluation Division at MFDS, said, “We have disclosed the reevaluation